Oxybutynin Chloride Tablets Recalled for Potential Labeling Error
Aidapak Services is recalling Oxybutynin Chloride tablets that may be mislabeled as Pimozide. The error could lead to patients receiving the wrong medication.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation that might cause temporary or medically reversible adverse health consequences. The source text describes a labeling mixup without reported injuries, fitting the criteria for a moderate severity score.
Plain-English summary
Aidapak Services, LLC is recalling Oxybutynin Chloride tablets, 2.5 mg, NDC 00603497521. The recall is due to a labeling error where the product may have been mislabeled as Pimozide tablets, 1 mg, NDC 57844018701. The affected Oxybutynin Chloride tablets have the pedigree AD73525_64 and an expiration date of 5/30/2014.
The repacked drugs were distributed in Arizona, California, Oregon, and Washington. The source text does not specify the number of units affected or report any illnesses or injuries associated with this labeling error.
Patients and healthcare providers should check their medication labels. If the label indicates Pimozide but the patient was prescribed Oxybutynin Chloride, or vice versa, they should contact their healthcare provider or pharmacist for guidance before taking the medication.
The recalled product
- Product
- OXYBUTYNIN CHLORIDE, Tablet, 2.5 mg (1/2 of 5 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00603497521
- Manufacturer
- Aidapak Services, LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 199
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- OXYBUTYNIN CHLORIDE
- Tablet
- 2.5 mg (1/2 of 5 mg) has the following codes: Pedigree: AD73525_64
- EXP: 5/30/2014.
Distribution
Part of a larger recall action
This product is one of 265 recalled by Aidapak Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 265 products in this recall →Related recalls
Same manufacturer · Aidapak Services, LLC
See all →- ModerateAidapak Recalls Sennosides Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-29
- ModerateLevothyroxine Sodium Tablets Recalled for Potential Labeling Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Mislabeled Pantoprazole Sodium DR Tablets
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Nifedipine ER Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateSimvastatin Tablets Recalled for Potential Labeling Error
FDA (Drugs) · 2014-01-29
Same hazard · mis labeling
See all →- SevereImperio Distribution Recalls Beef Jerky Produced Without Federal Inspection
USDA FSIS · 2026-10-24
- HighJ K Patisserie Chocolate Chip Cookies Recalled for Undeclared Soy
FDA (Food) · 2026-10-14
- HighFreshPoint Recalls Cranberry Chicken Salad Wedges for Undeclared Egg Allergen
FDA (Food) · 2026-10-14
- HighJ K Patisserie & Bakery LLC Recalls Croissants for Undeclared Egg
FDA (Food) · 2026-10-14
- LowMindray ePM Series Patient Monitor Manuals Recalled for Alarm Clarification
FDA (Devices) · 2026-10-14
Similar recalls
- HighAidapak Recalls Labeled LamoTRIgine Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-22
- SevereFDA Recalls Pimozide Tablets Due to Potential Metoprolol Labeling Error
FDA (Drugs) · 2014-01-22
- SevereAidapak Recalls Citalopram Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-22
- SeverePimozide Tablets Recalled for Potential Labeling Mixup
FDA (Drugs) · 2014-01-22
- SevereFDA Recalls Tizanidine Tablets Due to Potential Labeling Error
FDA (Drugs) · 2014-01-22
- ModerateAidapak Recalls OXcarbazepine Tablets Due to Potential Labeling Error
FDA (Drugs) · 2014-01-22